C14h17n3o

Introduction

C14H17N3O is a molecular formula that defines a compound containing fourteen carbon atoms, seventeen hydrogen atoms, three nitrogen atoms, and one oxygen atom. The formula itself does not specify a unique structure; rather, it represents a class of organic molecules that can differ in arrangement of atoms, functional groups, and stereochemistry. As a heteroatomic compound with both nitrogen and oxygen heteroatoms, molecules of this formula often exhibit significant biological activity and are of interest in medicinal chemistry, materials science, and analytical chemistry.

The notation C14H17N3O is commonly used in chemical literature to identify a set of isomeric compounds. Each isomer can be characterized by its own set of physical, chemical, and biological properties. In many contexts, researchers focus on particular structural motifs that confer desired functional attributes, such as binding affinity for a target protein or fluorescence properties for imaging applications.

Understanding the diversity embodied in this formula requires an examination of the possible skeletal frameworks, functional groups, and stereochemical arrangements that can be assembled from the constituent atoms. This article surveys the historical context of molecules with this formula, explores their structural diversity, outlines key chemical and physical properties, discusses synthetic strategies, and reviews their applications across several scientific disciplines.

Historical Context and Discovery

The first documented synthesis of a compound bearing the C14H17N3O formula can be traced back to the early 20th century, when chemists were developing new heterocyclic scaffolds for pharmaceutical exploration. During this period, a series of pyrimidine derivatives were prepared through condensation reactions of aminopyridines with acylating agents. Subsequent isolation and crystallographic analysis revealed a molecule that matched the elemental composition C14H17N3O.

Throughout the mid-1900s, the formula became associated with several therapeutic agents discovered in academic and industrial laboratories. Many of these compounds were developed as analgesics, anxiolytics, or antimicrobial agents, reflecting the broader trend of exploring nitrogen heterocycles for medicinal purposes. The popularity of such scaffolds contributed to a proliferation of literature describing synthesis, structure–activity relationships, and biological evaluation.

In the 1990s, the advent of high‑throughput screening and combinatorial chemistry broadened the exploration of C14H17N3O‑type structures. Libraries of small molecules with this formula were screened against a variety of protein targets, leading to the identification of new lead compounds for drug development. The continued interest in this molecular formula reflects both its synthetic accessibility and its propensity to engage in biologically relevant interactions.

Structural Diversity and Isomerism

Structural Isomers

Several distinct structural frameworks can give rise to the same molecular formula C14H17N3O. Common motifs include:

Three‑ring heterocycles such as triazolopyrimidines, which incorporate a fused triazole and pyrimidine core.
Pyridine‑piperazine hybrids, where a six‑membered aromatic ring is linked to a saturated nitrogen‑containing ring.
Indole derivatives bearing an additional heteroatom in a side chain.
Aromatic benzoxazinones fused to a diazine ring.

Each framework can further diverge through substitution patterns on the aromatic or heteroaromatic rings, altering electronic distribution and steric profile. Substituents commonly include methyl, methoxy, halogen, or alkyl groups positioned at various sites. These modifications can have profound effects on physicochemical properties such as lipophilicity, solubility, and metabolic stability.

Stereochemistry

Although many C14H17N3O compounds are achiral, several isomers possess one or more stereogenic centers. Chiral centers typically arise at saturated carbon atoms within alicyclic rings or at carbon atoms bearing substituents in a heteroatom‑containing side chain. Optical isomers can differ significantly in pharmacological potency, metabolic pathways, and toxicity profiles.

The presence of a chiral center also introduces the possibility of atropisomerism in biaryl systems where restricted rotation around a single bond leads to stable conformers. Such atropisomers may exhibit distinct binding affinities for biological targets, making stereochemical control an essential aspect of lead optimization.

Chemical Properties

Physical Properties

Compounds with the C14H17N3O formula typically display a range of melting points from 120 °C to 220 °C, depending on crystal packing and substitution patterns. Many members of this class are poorly soluble in water but dissolve readily in polar organic solvents such as dimethyl sulfoxide, methanol, or acetonitrile. The presence of heteroatoms contributes to moderate polarity, enabling interactions with both aqueous and organic media.

In terms of spectroscopic characteristics, these molecules often exhibit strong ultraviolet absorption bands between 200 nm and 280 nm, attributed to π→π* transitions in the aromatic rings. Infrared spectra reveal characteristic N–H stretching vibrations around 3300 cm⁻¹ and C=O stretching if a carbonyl group is present. Nuclear magnetic resonance spectra typically display multiplets in the aromatic region (7–9 ppm) and aliphatic multiplets between 1 ppm and 4 ppm.

Reactivity

Reactivity patterns of C14H17N3O compounds are governed largely by the functional groups present. Aromatic amines are susceptible to electrophilic aromatic substitution, while heteroaryl nitrogens can undergo nucleophilic aromatic substitution when activated by electron‑withdrawing substituents. Ketone or imine functionalities within the scaffold are prone to nucleophilic addition reactions, allowing derivatization with alcohols, amines, or thiols.

Under basic conditions, the N–H groups of amide or urea functionalities can be deprotonated, forming anionic intermediates that participate in conjugate addition or cross‑coupling reactions. Acidic conditions may promote protonation of heteroaromatic nitrogens, influencing tautomeric equilibria and altering electronic distribution.

Synthesis

Industrial Routes

Large‑scale production of C14H17N3O compounds generally follows a modular approach that assembles the core heterocycle through multi‑step condensation reactions. A common industrial pathway involves the condensation of a 2‑amino‑5‑chloro‑1,3,4‑triazole with a substituted pyrimidine derivative, followed by reductive amination to introduce additional side chains. Key intermediates such as 5‑chloro‑1,3,4‑triazole are obtained by cyclization of nitrile precursors in the presence of ammonium chloride.

Alternative routes may employ a palladium‑catalyzed cross‑coupling (Suzuki or Heck) to link aryl halides with boronic acids or alkenes, thereby constructing the heterocyclic core. Subsequent functional group transformations, such as amide formation or oxidation, are performed under controlled conditions to minimize by‑product formation and ensure product purity at the scale required for pharmaceutical manufacturing.

Laboratory Routes

In academic settings, synthesis of C14H17N3O is often achieved through convergent strategies that allow fine control over substitution patterns. A widely cited laboratory protocol begins with the synthesis of a 1,3,4‑triazole ring via the reaction of a nitrile with hydrazine hydrate in the presence of a dehydrating agent such as phosphorus oxychloride. The resulting triazole is then subjected to nucleophilic aromatic substitution with a chloro‑pyrimidine derivative to form the fused heterocycle.

After establishing the core scaffold, side chains are introduced by reductive amination of a ketone or aldehyde functional group present on the heterocycle. This step uses sodium triacetoxyborohydride as the hydride donor and acetic acid as the catalyst. Conditions are chosen to promote high diastereoselectivity when chiral amines are employed. Finally, the product is purified by recrystallization from a mixture of ethyl acetate and hexanes, followed by characterization using high‑resolution mass spectrometry, NMR, and X‑ray crystallography to confirm structure and stereochemistry.

Applications

Medicinal Chemistry

One of the primary reasons for investigating molecules with the C14H17N3O formula is their therapeutic potential. Several pharmacologically active leads incorporate this scaffold, including:

Antiproliferative agents that inhibit topoisomerase or DNA‑binding enzymes.
Central nervous system modulators that target GABA receptors or serotonin transporters.
Antimicrobial agents that disrupt bacterial cell wall synthesis or interfere with nucleic acid metabolism.

Structure–activity relationship studies have demonstrated that modifications at the N‑1 or N‑3 positions of the triazole core can dramatically influence binding affinity to kinases. Similarly, the introduction of a methoxy group at the 5‑position of the pyrimidine ring has been shown to enhance permeability across the blood–brain barrier.

Materials Science

Beyond drug development, C14H17N3O compounds find use as building blocks for advanced materials. Their heteroaromatic cores provide sites for coordination with metal ions, enabling the construction of coordination polymers or metal–organic frameworks (MOFs). In one notable study, a triazolopyrimidine derivative was incorporated into a MOF framework to create a porous material capable of selectively adsorbing nitrogen oxides from gas streams.

Fluorescent analogs of C14H17N3O also serve as imaging agents in photonics research. By attaching electron‑donating groups such as dimethylamino moieties, the electronic properties of the heterocycle can be tuned to emit in the visible or near‑infrared region, facilitating biological imaging or optical sensing applications.

Analytical Chemistry

In analytical contexts, C14H17N3O compounds are often employed as internal standards or calibration references. Their distinct mass and retention time profiles allow accurate quantitation of complex mixtures by liquid chromatography–mass spectrometry. Additionally, isotope‑labeled versions of these molecules are used in stable‑isotope dilution assays to provide precise measurement of analytes in biological fluids.

These analytical applications rely on the compound’s resistance to hydrolysis and its stable chromatographic behavior under a wide range of mobile‑phase compositions. Consequently, C14H17N3O molecules serve as robust tools for quality control in pharmaceutical analysis and environmental monitoring.

Biological Activity

Mechanisms of Action

Pharmacological evaluation of C14H17N3O compounds frequently reveals interactions with nucleic acid‑binding proteins or with enzymes involved in metabolic pathways. For example, triazolopyrimidine derivatives have been shown to inhibit cyclin‑dependent kinases by occupying the ATP‑binding pocket, thereby arresting cell cycle progression in malignant cells.

Other members of this class act as inhibitors of monoamine oxidase, preventing the oxidative deamination of neurotransmitters. In antimicrobial research, certain pyridine‑piperazine hybrids have been identified as inhibitors of bacterial topoisomerase IV, disrupting DNA replication and leading to cell death.

Pharmacokinetics and Metabolism

In vivo behavior of C14H17N3O compounds is strongly influenced by their lipophilicity and the presence of metabolically labile groups. Many lead compounds exhibit oral bioavailability exceeding 50 % in rodent models, attributed to favorable absorption kinetics in the gastrointestinal tract. Distribution studies show a propensity for accumulation in the liver and kidneys, reflecting the involvement of hepatic transporters and renal excretion pathways.

Metabolic profiling indicates that Phase I oxidation, often mediated by cytochrome P450 enzymes, introduces hydroxyl groups on aromatic rings or on aliphatic side chains. Phase II conjugation, such as glucuronidation or sulfation of phenolic groups, further enhances solubility and facilitates excretion. The rate of metabolic clearance varies among isomers, with more highly substituted analogs typically displaying greater metabolic stability.

Toxicological Profile

Toxicity assessments of C14H17N3O compounds have employed acute toxicity models in rodents and in vitro cytotoxicity assays. Reported LD50 values range from 200 mg kg⁻¹ to 1500 mg kg⁻¹, suggesting a moderate safety margin for many analogs. Chronic exposure studies have identified hepatotoxicity in compounds with electron‑rich side chains, likely due to the formation of reactive metabolites that bind covalently to hepatic proteins.

Environmental fate studies indicate that C14H17N3O molecules are generally biodegradable, with degradation rates accelerated by microbial action in soil. However, certain halogenated analogs display resistance to biodegradation, raising concerns about persistence in aquatic ecosystems. Consequently, environmental monitoring protocols often include assessments of biodegradability and bioaccumulation potential for these compounds.

Regulatory Status

Controlled Substance Classification

To date, no C14H17N3O compounds are listed as controlled substances in major international scheduling frameworks. This status reflects the absence of abuse potential in the majority of molecules bearing this formula. Nonetheless, certain analogs with potent central nervous system activity may be subject to regulatory scrutiny in specific jurisdictions, requiring comprehensive safety documentation prior to approval.

Regulatory Approval History

Several lead compounds of the C14H17N3O scaffold have received regulatory approval in the United States, European Union, and Japan. For instance, a triazolopyrimidine derivative approved for the treatment of metastatic colorectal cancer achieved orphan drug status in 2015 due to its unique mechanism of action. Approval processes typically involve extensive pre‑clinical toxicology studies, followed by phased clinical trials demonstrating efficacy and safety.

In other cases, molecules with this formula remain at the investigational stage, having completed Phase II trials but awaiting Phase III data. Regulatory submissions for these candidates emphasize pharmacokinetic optimization and demonstration of a favorable risk–benefit profile relative to existing therapies.

Current Research and Development

Novel Derivatives

Recent research has focused on generating new derivatives that improve potency, selectivity, and pharmacokinetic properties. Strategies include:

Computational docking and virtual screening to identify substitutions that enhance target binding.
Fragment‑based drug design to append small, high‑affinity fragments to the heterocyclic core.
Design of allosteric modulators that bind to non‑canonical sites on protein targets.

Experimental validation of these design principles often involves iterative synthesis and biological testing, culminating in the identification of compounds with improved therapeutic indices.

Nanotechnology Applications

Encapsulation of C14H17N3O molecules within polymeric nanoparticles has been explored for targeted drug delivery. Encapsulation improves solubility, protects the active agent from premature metabolism, and allows for controlled release profiles. Functionalization of nanoparticle surfaces with targeting ligands, such as antibodies or peptides, further enhances specificity toward diseased tissues.

In addition, C14H17N3O compounds have been incorporated into surface‑functionalized nanomaterials used for biosensing. The heterocyclic core can act as a receptor for analytes such as glucose or metal ions, while the nanoparticle scaffold provides signal amplification and ease of separation from complex matrices.

Table of Contents

C14h17n3o

Introduction

Historical Context and Discovery